A Placebo Controlled Phase III Double Blind Study of ITK-1 in Patients with Prostate Cancer - A Clinical Evaluation of ITK-1 in Castration-Resistant, Docetaxel Refractory Prostate Cancer Patients with HLA-A24 positive -Confirmatory Study
Phase of Trial: Phase III
Latest Information Update: 29 May 2018
Price : $35 *
At a glance
- Drugs ITK 1 (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors BrightPath Biotherapeutics
- 22 May 2018 Status changed from active, no longer recruiting to completed.
- 01 Jul 2017 Company name changed from Green Peptide Corporation to BrightPath Biotherapeutics Co., Ltd.
- 01 Aug 2016 Status changed from recruiting to active, no longer recruiting.